Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - calcitriolum - weichgelatinekapseln - calcitriolum 0.25 µg, antiox.: e 320, e 321, excipiens per la capsula. - renale osteodystrophie, ipoparatiroidismo, rachitismo, osteoporosi post-menopausa - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - calcitriolum - weichgelatinekapseln - calcitriolum 0.5 µg, antiox.: e 320, e 321, excipiens per la capsula. - renale osteodystrophie, ipoparatiroidismo, rachitismo, osteoporosi post-menopausa - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

vifor fresenius medical care renal pharma ltd. - calcifediolum - weichkapseln retardiert - calcifediolum 30 µg ut calcifediolum monohydricum, paraffinum solidum, paraffinum liquidum, hypromellosum, glyceroli monostearas 40-55, macrogolglyceridorum laurates, ethanolum anhydricum 3.944 mg, e 321, kapselhülle: amylum hydroxypropylum, carrageenanum, sorbitolum liquidum partim deshydricum corresp. sorbitolum 18 mg, dinatrii phosphas corresp. natrium 0.3 mg, titanii dioxidum, e 133, aqua purificata pro capsula. - rayaldee ist zur behandlung von sekundärem hyperparathyreoidismus (shpt) bei erwachsenen mit chronischer niereninsuffizienz (ckd) im stadium 3 oder 4 und 25- hydroxyvitamin-d-serumwerten <30 ng/ml indiziert. - synthetika

Itàlia - italià - AIFA (Agenzia Italiana del Farmaco)

schering spa - calcitriolo - calcitriolo

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

leo pharmaceutical products sarath ltd. - calcipotriolum, betamethasonum - salve - calcipotriolum 0.05 mg ut calcipotriolum monohydricum, betamethasonum 0.5 mg ut betamethasoni dipropionas, paraffinum liquidum, polyoxypropyleni 11 aether stearylicus, e 307, e 321 0.05 mg, vaselinum album, ad unguentum pro 1 g. - la psoriasi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

leo pharmaceutical products sarath ltd. - calcipotriolum, betamethasonum - gel - calcipotriolum 50 µg ut calcipotriolum monohydricum, betamethasonum 0.5 mg ut betamethasoni dipropionas, paraffinum liquidum, polyoxypropyleni 11 aether stearylicus, ricini oleum hydrogenatum, e 307, e 321 160 µg, ad gelatum pro 1 g. - la psoriasi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

leo pharmaceutical products sarath ltd. - calcipotriolum, betamethasonum - gel - calcipotriolum 50 µg ut calcipotriolum monohydricum, betamethasonum 0.5 mg ut betamethasoni dipropionas, paraffinum liquidum, polyoxypropyleni 11 aether stearylicus, ricini oleum hydrogenatum, e 307, e 321 160 µg, ad gelatum pro 1 g. - la psoriasi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

leo pharmaceutical products sarath ltd. - calcipotriolum, betamethasonum - schiuma per l'applicazione sulla pelle - calcipotriolum 50 µg ut calcipotriolum monohydricum, betamethasonum 0.5 mg ut betamethasoni dipropionas, polyoxypropyleni 11 aether stearylicus, paraffinum liquidum, vaselinum album, e 321 50 µg, e 307, ad unguentum pro 1 g, propellentia: butanum et ether dimethylicus. - psoriasi vulgaris - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

leo pharmaceutical products sarath ltd - calcipotriolum, betamethasonum - gel con applicatore - calcipotriolum 50 µg per calcipotriolum monohydricum, betamethasonum 0,5 mg per betamethasoni dipropionas, excipiens annuncio gelatum pro 1 g. - la psoriasi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

dermapharm ag - calcipotriolum, betamethasonum - salve - calcipotriolum 50 µg ut calcipotriolum monohydricum, betamethasonum 0.5 mg ut betamethasoni dipropionas, polyoxypropyleni 11 aether stearylicus, e 321 max. 75 µg, paraffinum liquidum, vaselinum album, e 307, ad unguentum pro 1 g. - la psoriasi - synthetika